Lyell Immunopharma Inc.

NASDAQ: LYEL · Real-Time Price · USD
10.62
-0.14 (-1.30%)
At close: Aug 15, 2025, 3:59 PM
10.58
-0.38%
After-hours: Aug 15, 2025, 04:10 PM EDT

Lyell Immunopharma Balance Sheet Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Cash & Equivalents
105.6M 145.65M 123.55M 293.83M
Short-Term Investments
264.93M 400.58M 516.6M 320.97M
Long-Term Investments
32.01M 48.51M 115.04M 330.53M
Other Long-Term Assets
6.31M 4.52M 4.96M 3.95M
Receivables
n/a n/a n/a n/a
Inventory
n/a n/a n/a n/a
Other Current Assets
9.07M 8.46M 11.14M 11.49M
Total Current Assets
379.59M 554.69M 651.29M 626.29M
Property-Plant & Equipment
72.94M 142.32M 166.26M 166.64M
Goodwill & Intangibles
n/a n/a n/a n/a
Total Long-Term Assets
111.27M 195.34M 286.27M 501.12M
Total Assets
490.86M 750.03M 937.56M 1.13B
Account Payables
5.37M 4.82M 3.92M 3.21M
Deferred Revenue
n/a n/a 21.87M 4.99M
Short-Term Debt
7.97M n/a n/a n/a
Other Current Liabilities
14.74M 8.79M 13.13M 20.08M
Total Current Liabilities
53.79M 34.52M 37.03M 46.74M
Long-Term Debt
n/a n/a 63.17M 66.65M
Other Long-Term Liabilities
3.25M 3.66M -59.05M -62.08M
Total Long-Term Liabilities
54.25M 60.56M 67.28M 150.88M
Total Liabilities
108.03M 95.08M 104.31M 197.62M
Total Debt
58.97M 63.17M 67.7M 67.82M
Common Stock
29K 25K 25K 24K
Retained Earnings
-1.35B -1B -767.48M -584.36M
Comprehensive Income
291K -94K -7.6M -1.62M
Shareholders Equity
382.82M 654.95M 833.25M 929.79M
Total Investments
296.94M 449.08M 631.64M 651.5M